Prostate cancer is the second leading cause of cancer-related deaths in men in most western countries.
New agents for metastatic castration-resistant prostate cancer (CRPC) developed in the past 3 years include abiraterone acetate (AA) and enzalutamide (ENZ), which inhibit signaling by and synthesis of androgens, respectively. Because they share the same target, potential clinical cross-resistance between AA and E is possible. In this review, we discuss the results of clinical studies in which CRPC patients were treated with AA and E either separately or in sequence after first-line treatment with docetaxel. Our review suggests that sequential administration of AA and E in either order has limited activity after docetaxel therapy. Prospective studies that further examine sequential treatments with AA and E are warranted.
Written by:
Francini E, Petrioli R, Roviello G. Are you the author?
Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Via del Policlinico 155, 00161 Roma, Italy.
Reference: Expert Rev Anticancer Ther. 2014 Aug 19:1-6.
doi: 10.1586/14737140.2014.949677
PubMed Abstract
PMID: 25135334